Hb responders at any time during treatment (all cohorts)
| . | Placebo or etavopivat once daily . | |||
|---|---|---|---|---|
| MAD placebo 0 mg . | MAD1 300 mg . | MAD2 600 mg . | OL 400 mg . | |
| Wk | 2 | 2 | 2 | 12 |
| Number of patients, n | 4 | 8 | 8 | 15 |
| Maximal Hb increase, mean (range), g/dL | 0.4 (0.0-0.6) | 1.4 (0.4-2.4) | 1.4 (0.2-3.5) | 1.6 (0.8-2.8) |
| Hb increase >1 g/dL response on treatment, n (%) | 0 | 7 (87.5) | 4 (50.0) | 11 (73.3) |
| Maximal Hb increase in patients with >1 g/dL response, mean (range), g/dL | NA | 1.5 (1.1-2.4) | 2.2 (1.5-3.5) | 1.9 (1.2-2.8) |
| . | Placebo or etavopivat once daily . | |||
|---|---|---|---|---|
| MAD placebo 0 mg . | MAD1 300 mg . | MAD2 600 mg . | OL 400 mg . | |
| Wk | 2 | 2 | 2 | 12 |
| Number of patients, n | 4 | 8 | 8 | 15 |
| Maximal Hb increase, mean (range), g/dL | 0.4 (0.0-0.6) | 1.4 (0.4-2.4) | 1.4 (0.2-3.5) | 1.6 (0.8-2.8) |
| Hb increase >1 g/dL response on treatment, n (%) | 0 | 7 (87.5) | 4 (50.0) | 11 (73.3) |
| Maximal Hb increase in patients with >1 g/dL response, mean (range), g/dL | NA | 1.5 (1.1-2.4) | 2.2 (1.5-3.5) | 1.9 (1.2-2.8) |
Only measurements up to EOT were included.
Hb, hemoglobin; MAD, multiple ascending dose; NA, not assessed; OL, open-label.